Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

AI Summary

Merck is seen as a buy due to a strong pipeline of cancer drugs offsetting the impact of the Keytruda patent expiration, according to Morgan Stanley. Upcoming drug launches are expected to sustain Merck's growth in oncology markets.

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.